Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Microvillus Inclusion Disease

  • Author: Stefano Guandalini, MD; Chief Editor: Carmen Cuffari, MD  more...
 
Updated: Jul 17, 2015
 

Background

Microvillus inclusion disease (also referred to as congenital microvillus atrophy) is, with Tuft enteropathy, the best known disease of the intestinal epithelium causing intractable diarrhea of infancy, and a leading cause of secretory diarrhea in the first weeks of life. A group of infants with a familial enteropathy characterized by protracted diarrhea from birth and villus hypoplastic atrophy had been described in 1978 by Davidson et al.[1] The term microvillus atrophy was first used to identify the disease in 1982. The typical clinical presentation is watery profuse secretory diarrhea starting in the first hours of life. The peak age of onset is the early neonatal period. Although later-onset cases have been described, cases have never been described beyond the first 2-3 months of life.

Three variants of the disease have been identified: Microvillus inclusion disease, late-onset microvillus inclusion disease, and atypical microvillus inclusion disease.

In microvillus inclusion disease, diarrhea starts in the first few days of life and is immediately life threatening. Oral alimentation in nutritionally significant amounts is impossible. In late-onset microvillus inclusion disease, diarrhea starts later in life, usually in the second month. Diarrhea tends to be less severe than in the other form, and some alimentation is possible. A few cases have been termed atypical microvillus inclusion disease, in which the onset can be congenital or late, but the histologic picture is different.

The hallmark of the disease is the electron microscopic finding of disrupted enterocyte microvilli (ie, digitations of the apical membrane of the intestinal epithelial cell protruding into the lumen) and the appearance of characteristic inclusion vacuoles, the inner surfaces of which are lined by typical microvilli. Both lesions are seen only on electronic microscopy. In a notable percentage of consanguineous families, more than one child is affected; therefore, the disease appears to be transmitted as an autosomal recessive trait.

Next

Pathophysiology

The pathogenesis of the disease, that had remained elusive for a long time, appears now to be associated with patient-unique, family-unique, and ancestry-unique mutations in the MYO5B gene, encoding the actin-based motor protein myosin Vb.

These mutations lead to severe perturbation of the microvillar cytoskeleton disrupting the transport of brush border components that have to be assembled at the apical membrane.

Biopsy samples from the small intestine of 2 infants with congenital microvillus inclusion disease were examined to analyze the membrane protein of the brush border. The samples demonstrated striking diminutions of the myosin bands. The genetic defect appears likely to cause abnormal binding of the myosin to the actin cable. In one patient with late-onset microvillus atrophy, the molecular defect involved a different protein, supposedly identified as vinculin.

Other studies have suggested an alternative hypothesis, namely that a defect in the autophagocytosis pathway[2] or an increase in enterocyte apoptosis and proliferation[3] explains the abnormalities observed in congenital microvillous disease.

Recently, Dutch investigators have found[4] that the mild variant of microvillus inclusion disease appears to be caused by loss of function of syntaxin 3 (STX3), an apical receptor involved in membrane fusion of apical vesicles in enterocytes. In fact, whole-exome sequencing of DNA from patients with variant microvillus inclusion disease revealed homozygous truncating mutations in STX3; and in addition, patient-derived organoid cultures and overexpression of truncated STX3 in CaCo2 cells recapitulated most characteristics of variant microvillus inclusion disease.

The postulated abnormality in the cytoskeleton causes a block in exocytosis, mainly of periodic acid-Schiff (PAS)–positive material (eg, polysaccharides, glycoproteins, glycolipids, neutral mucopolysaccharides). As a consequence, small secretory granules that contain a PAS-positive material accumulate in the apical cytoplasm of epithelial cells.

Substantial progress has been made in identifying the molecular nature of the secretory granules. A neutral, blood group antigen–positive glycosubstance that contains acetylated sialic acid accumulates in these granules. Acetylated sialic acid has been identified as a common component of the glycocalyx, suggesting that microvillus atrophy involves a defect in exocytosis of the glycocalyx or some of its components. To support this possibility, immunoreactivity against glycocalyx is found in secretory granules in microvillus atrophy.

The microvilli in the brush border are scanty, disorganized, and short.

Because of these alterations, mature enterocytes inefficiently absorb ions and nutrients, causing a malabsorption syndrome; however, the diarrhea is caused mainly by active secretion of water and electrolytes in the intestinal lumen (secretory diarrhea). The pathogenesis of the secretory diarrhea is unknown; it is assumed to result from an unbalance between decreased absorption and unaltered secretion. Data suggest that the morphologic changes of the disease result in a secondary decrease in the amount of messenger RNA (mRNA) encoding for apical membrane-transport systems.

Previous
Next

Epidemiology

Frequency

United States

A cluster of cases from the Navajo reservation in northern Arizona suggests an incidence as high as 1 case per 12,000 live births.

International

A survey completed in 1987 among centers known for their involvement in pediatric gastroenterology identified more than 30 cases worldwide. Additional cases were later published, including a series of 17 cases from the United Kingdom between 1990-2008[5] . Typical microvillus inclusion disease accounts for 80% of cases. The remaining 20% are due to mainly late-onset disease.

To better define this rare condition and its prevalence worldwide, an online MOLGENIS-based international patient registry has been constructed.[6] This easily accessible database currently contains detailed information of 137 patients with microvillus inclusion disease together with reported clinical/phenotypic details and 41 unique MYO5B mutations, several of which unpublished.

Mortality/Morbidity

The survival of patients with typical cases depends on total parenteral nutrition (TPN). Most infants of early series died when aged 3-9 months. The leading causes of death were dehydration, malnutrition, and sepsis.

Successful outcomes of small intestinal transplantation have been reported, and evidence suggests that an early transplant might be beneficial.[7, 8, 9] However, the prognosis remains poor, with most patients dying by the second decade of life as a result of complications of parenteral alimentation. Even patients who have undergone small-bowel transplantation have a mean 5-year survival rate of about 50%. Patients with late-onset or variant microvillus inclusion disease appear to have an improved prognosis.

Sex

A female preponderance has been observed among the published cases, with a female-to-male ratio of 2:1.

Age

The classic form of microvillus inclusion disease appears in the first 72 hours of life (usually on the first day) and is immediately life threatening. Late-onset microvillus atrophy starts after 6-8 weeks in a normal-appearing infant.

Previous
 
 
Contributor Information and Disclosures
Author

Stefano Guandalini, MD Founder and Medical Director, Celiac Disease Center, Chief, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Chicago Medical Center; Professor, Department of Pediatrics, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine

Stefano Guandalini, MD is a member of the following medical societies: American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, European Society for Paediatric Gastroenterology, Hepatology & Nutrition, North American Society for the Study of Celiac Disease

Disclosure: Received consulting fee from AbbVie for consulting.

Coauthor(s)

Agostino Nocerino, MD, PhD Chief of Pediatric Oncology, Department of Pediatrics, University of Udine, Italy

Agostino Nocerino, MD, PhD is a member of the following medical societies: American Society of Pediatric Hematology/Oncology, Italian Society of Pediatric Hematology and Oncology, Italian Society of Pediatric Emergency and Urgent Care Medicine, Italian Society of Pediatrics

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Carmen Cuffari, MD Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine

Carmen Cuffari, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, Royal College of Physicians and Surgeons of Canada

Disclosure: Received honoraria from Prometheus Laboratories for speaking and teaching; Received honoraria from Abbott Nutritionals for speaking and teaching.

Additional Contributors

Chris A Liacouras, MD Director of Pediatric Endoscopy, Division of Gastroenterology and Nutrition, Children's Hospital of Philadelphia; Associate Professor of Pediatrics, University of Pennsylvania School of Medicine

Chris A Liacouras, MD is a member of the following medical societies: American Gastroenterological Association

Disclosure: Nothing to disclose.

References
  1. Davidson GP, Cutz E, Hamilton JR, Gall DG. Familial enteropathy: a syndrome of protracted diarrhea from birth, failure to thrive, and hypoplastic villus atrophy. Gastroenterology. 1978 Nov. 75(5):783-90. [Medline].

  2. Reinshagen K, Naim HY, Zimmer KP. Autophagocytosis of the apical membrane in microvillus inclusion disease. Gut. 2002 Oct. 51(4):514-21. [Medline].

  3. Groisman GM, Sabo E, Meir A, Polak-Charcon S. Enterocyte apoptosis and proliferation are increased in microvillous inclusion disease (familial microvillous atrophy). Hum Pathol. 2000 Nov. 31(11):1404-10. [Medline].

  4. Wiegerinck CL, Janecke AR, Schneeberger K, Vogel GF, van Haaften-Visser DY, Escher JC, et al. Loss of Syntaxin 3 Causes Variant Microvillus Inclusion Disease. Gastroenterology. 2014 Apr 8. [Medline].

  5. Al-Daraji WI, Zelger B, Zelger B, Hussein MR. Microvillous inclusion disease: a clinicopathologic study of 17 cases from the UK. Ultrastruct Pathol. 2010 Dec. 34(6):327-32. [Medline].

  6. van der Velde KJ, Dhekne HS, Swertz MA, Sirigu S, Ropars V, Vinke PC. An overview and online registry of microvillus inclusion disease patients and their MYO5B mutations. Hum Mutat. 2013 Dec. 34(12):1597-605. [Medline].

  7. Herzog D, Atkison P, Grant D, et al. Combined bowel-liver transplantation in an infant with microvillous inclusion disease. J Pediatr Gastroenterol Nutr. 1996 May. 22(4):405-8. [Medline].

  8. Oliva MM, Perman JA, Saavedra JM, et al. Successful intestinal transplantation for microvillus inclusion disease. Gastroenterology. 1994 Mar. 106(3):771-4. [Medline].

  9. Ruemmele FM, Jan D, Lacaille F, et al. New perspectives for children with microvillous inclusion disease: early small bowel transplantation. Transplantation. 2004 Apr 15. 77(7):1024-8. [Medline].

  10. Kennea N, Norbury R, Anderson G, Tekay A. Congenital microvillous inclusion disease presenting as antenatal bowel obstruction. Ultrasound Obstet Gynecol. 2001 Feb. 17(2):172-4. [Medline].

  11. Chen CP, Su YN, Chern SR, Wu PC, Wang W. Prenatal diagnosis of microvillus inclusion disease. Taiwan J Obstet Gynecol. 2011 Sep. 50(3):399-400. [Medline].

  12. Ruemmele FM, Schmitz J, Goulet O. Microvillous inclusion disease (microvillous atrophy). Orphanet J Rare Dis. 2006 Jun 26. 1:22. [Medline].

  13. Burgis JC, Pratt CA, Higgins JP, Kerner JA. Multiple hepatic adenomas in a child with microvillus inclusion disease. Dig Dis Sci. 2013 Oct. 58(10):2784-8. [Medline].

  14. Weeks DA, Zuppan CW, Malott RL, Mierau GW. Microvillous inclusion disease with abundant vermiform, electron-lucent vesicles. Ultrastruct Pathol. 2003 Sep-Oct. 27(5):337-40. [Medline].

  15. Iancu TC, Mahajnah M, Manov I, Shaoul R. Microvillous inclusion disease: ultrastructural variability. Ultrastruct Pathol. 2007 May-Jun. 31(3):173-88. [Medline].

  16. Groisman GM, Amar M, Livne E. CD10: a valuable tool for the light microscopic diagnosis of microvillous inclusion disease (familial microvillous atrophy). Am J Surg Pathol. 2002 Jul. 26(7):902-7. [Medline].

  17. Youssef N, M Ruemmele F, Goulet O, Patey N. [CD10 expression in a case of microvillous inclusion disease]. Ann Pathol. 2004 Dec. 24(6):624-7. [Medline].

  18. Halac U, Lacaille F, Joly F, Hugot JP, Talbotec C, Colomb V, et al. Microvillous inclusion disease: how to improve the prognosis of a severe congenital enterocyte disorder. J Pediatr Gastroenterol Nutr. 2011 Apr. 52(4):460-5. [Medline].

  19. Phillips AD, Schmitz J. Familial microvillous atrophy: a clinicopathological survey of 23 cases. J Pediatr Gastroenterol Nutr. 1992 May. 14(4):380-96. [Medline].

  20. Assmann B, Hoffmann GF, Wagner L, et al. Dihydropyrimidinase deficiency and congenital microvillous atrophy: coincidence or genetic relation?. J Inherit Metab Dis. 1997 Sep. 20(5):681-8. [Medline].

  21. Carruthers L, Dourmashkin R, Phillips A. Disorders of the cytoskeleton of the enterocyte. Clin Gastroenterol. 1986 Jan. 15(1):105-20. [Medline].

  22. Cutz E, Rhoads JM, Drumm B, et al. Microvillus inclusion disease: an inherited defect of brush-border assembly and differentiation. N Engl J Med. 1989 Mar 9. 320(10):646-51. [Medline].

  23. Michail S, Collins JF, Xu H, et al. Abnormal expression of brush-border membrane transporters in the duodenal mucosa of two patients with microvillus inclusion disease. J Pediatr Gastroenterol Nutr. 1998 Nov. 27(5):536-42. [Medline].

  24. Nathavitharana KA, Green NJ, Raafat F, Booth IW. Siblings with microvillous inclusion disease. Arch Dis Child. 1994 Jul. 71(1):71-3. [Medline].

  25. Pecache N, Patole S, Hagan R, et al. Neonatal congenital microvillus atrophy. Postgrad Med J. 2004 Feb. 80(940):80-3. [Medline].

  26. Phillips AD, Brown A, Hicks S, et al. Acetylated sialic acid residues and blood group antigens localise within the epithelium in microvillous atrophy indicating internal accumulation of the glycocalyx. Gut. 2004 Dec. 53(12):1764-71. [Medline].

  27. Phillips AD, Jenkins P, Raafat F, Walker-Smith JA. Congenital microvillous atrophy: specific diagnostic features. Arch Dis Child. 1985 Feb. 60(2):135-40. [Medline].

  28. Phillips AD, Szafranski M, Man LY, Wall WJ. Periodic acid-Schiff staining abnormality in microvillous atrophy: photometric and ultrastructural studies. J Pediatr Gastroenterol Nutr. 2000 Jan. 30(1):34-42. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.